Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cemiplimab - Regeneron Pharmaceuticals/Sanofi

Drug Profile

Cemiplimab - Regeneron Pharmaceuticals/Sanofi

Alternative Names: Cemiplimab-rwlc; Libtayo; REGN-2810; SAR-439684

Latest Information Update: 11 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Columbia University; Inovio Pharmaceuticals; ISA Pharmaceuticals; Regeneron Pharmaceuticals; Replimune; Sanofi; SillaJen Biotherapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Squamous cell cancer
  • Phase III Cervical cancer; Non-small cell lung cancer
  • Phase II Basal cell cancer; Glioblastoma; Head and neck cancer; Liver cancer; Oropharyngeal cancer; Prostate cancer
  • Phase I/II Fallopian tube cancer; Multiple myeloma; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Phase I B-cell lymphoma; Cancer; Malignant melanoma; Renal cell carcinoma

Most Recent Events

  • 04 Dec 2019 Regeneron Pharmaceuticals initiates a phase II trial for Squamous cell cancer (Neoadjuvant therapy, Metastatic disease) in USA (IV) (NCT04154943)
  • 14 Nov 2019 BioNTech and Regeneron enters into a clinical trial supply agreement to supply cemiplimab for a phase I/II trial in prostate cancer
  • 14 Nov 2019 BioNTech plans a phase I/II trial in Prostate cancer (Newly diagnosed, Metastatic disease, Hormone-refractory, Monotherapy, Combination therapy), in the fourth quarter of 2019 (BioNTech pipeline, November 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top